Analysis by Type (2.5mg/ml and 2mg/ml); by Route of Administration (Intravenous and Oral); by Application (Cancer, Autoimmune Diseases, Ectopic Pregnancy and Others); by End Users (Hospitals, Homecare, Specialty Clinics and Others); by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now
The global methotrexate drug market size is estimated to reach ~USD 850 million by the end of 2035 by growing at a CAGR of ~4% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of methotrexate drug was ~USD 590 million. The growth of the market can be attributed to the increasing prevalence of cancer and autoimmune disorders such as rheumatoid arthritis. According to the World Health Organization (WHO), cancer is the leading cause of death Worldwide with over 10 million deaths in 2020. Methotrexate which is a folate antagonist is widely used in the effective treatments of these disorders. The National Cancer Institute (NCI) listed methotrexate sodium as an approved drug for many clinical trials such as breast cancer, lung cancer. The increased use of methotrexate in chemotherapy treatments to treat rare, cancerous tumors is another factor that is predicted to increase the market in the years to come.
In addition to these, factors that are believed to fuel the market growth of methotrexate drugs include the new product launches and increased focus of gaining product approvals from regulatory bodies. For instance, on May, 2018, Hikma Pharmaceuticals PLC., announced the launch of methotrexate injections as 2mL vials. Additionally, Silvergate Pharmaceuticals announced FDA approval for XATMEP, the first and only ready to use oral methotrexate solution in the world. Additionally, the growing number of research and development activities on the production of methotrexate drugs is also predicted to present the potential for market expansion over the projected period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~4% |
|
Base Year Market Size (2022) |
~ USD 590 Million |
|
Forecast Year Market Size (2035) |
~ USD 850 Million |
|
Regional Scope |
|
Growth Drivers
Challenges
The global methotrexate drug market is segmented and analyzed for demand and supply by route of administration into intravenous and oral. Out of the two types of methotrexate drug administration, the intravenous segment is estimated to be growing at a CAGR ⁓16% in the forecast period. The growth of the segment can be attributed to the increasing efficacy of methotrexate intramuscular and subcutaneous injection for treatment of rheumatoid arthritis, cancer and others. For instance, research conducted by the Department of Immunology and Rheumatology, to compare efficacy of methotrexate injections and oral administration for treatment of rheumatoid arthritis, concluded that with intravenous injections there is improved clinical efficacy, tolerance and fewer side effects than with oral administration. It was also noted that the disease manifestations were improved with intravenous injections. This is anticipated to boost the market growth of the segment in coming years.
The global methotrexate drug market is also segmented and analyzed for demand and supply by end-user into hospital pharmacies, retail pharmacies and others. Amongst these three segments, the hospital pharmacies segment is expected to garner a significant share by the year 2035. Patients suffering from diseases such as such as cancer, auto-immune conditions- rheumatoid arthritis, lupus often visit hospitals for treatment, and it’s easier and convenient for them to purchase the prescribed drugs directly from the same hospital premises. On the other hand, the online pharmacies segment is projected to witness a massive CAGR during the forecast period, owing to the rising awareness for these online platforms amongst the users worldwide. Purchasing medicines online help the user to receive the prescribed drugs directly at their homes, without the need to visit offline stores. Besides this, methotrexate drugs are expensive and with mail orders the patient could avail discounts for the same. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global methotrexate drug market includes the following segments:
|
By Type |
|
|
By Administration |
|
|
By Application |
|
|
By End Users |
|
|
By Distribution Channel |
|
The market share of methotrexate drug in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~38% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of cancer, arthritis, psoriasis amongst people, backed by the change in lifestyle of individuals. For instance, the National Cancer Institute (NCI) estimated 1,806, 590 new cases in 2020 with a 606,520 patient’s death. The cancer incidence is reported as 442 per 100,000 men and women per year. Further, the presence of a strong healthcare network in the region, along with the presence of key manufacturers, are also anticipated to contribute to the market growth in the region. For instance, NORDIC Pharma has announced the submission of marketing authorization of methotrexate auto injector called Nordimet to the Health Canada. Nordimet helps in disabling rheumatoid arthritis and psoriasis in adults that are unresponsive to other treatment methods. The region's increasing R&D activities in creating new formulations of methotrexate drugs are also anticipated to boost the market growth during the forecast period.
The European methotrexate drug market is estimated to be the second largest by the end of 2035. The growth of the market can be attributed majorly to the increasing government monitoring, expenditure on healthcare industry, and new product launches. For instance, on 22 August, 2019 European Medicines Agency announced strict monitoring for methotrexate dosing and newer measures were introduced for better dosage of the drug and its efficacy. On 15th February, 2022, AbbVie announced that the European Commission has approved SKYRIZI to be used with methotrexate to effectively treat psoriatic arthritis in adults. Further, the presence of a strong healthcare network in the region, along with the availability of supportive policies by the regulatory bodies are also anticipated to contribute to the market growth in the region. In addition, the region's expanding healthcare industry and newer method adoption for treatment of Psoriasis and other skin conditions using low doses of methotrexate are also anticipated to boost the market growth during the forecast period.
Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of disorders such as cancer, auto-immune conditions and other disorders that use methotrexate for effective management. An increase of women choosing abortions is yet another reason for the market growth. For instance, according to the World Health Organization (WHO), less than half of abortions in South and Central Asia are safe. It was also estimated that illegal abortions in countries such as India, Bangladesh, Nepal range from 58% to over 90%. The use of methotrexate along with misoprostol to terminate pregnancy could pave way to safer abortions with lower mortality rate. Further, the upsurge in the healthcare network and expenditure in the region are also anticipated to contribute to the market growth in the region.
Teva and Celltrion announced the launch of Truxima injection for effective treatment of rheumatoid arthritis. The drug that is similar to Rituxan is used with methotrexate for treatment of inflammatory arthritis. The product received approval from the approval from the US Food and Drug Administration.
Amgen introduces Amjevita, a biosimilar to AbbVie’s Humira. This FDA approved drug along with methotrexate is expected to reduce signs and symptoms of structural damage and help treat rheumatoid, psoriatic arthritis.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Increasing incidences of arthritis, application of methotrexate in cancer treatments, combination therapy, increasing approval rates of the drug, awareness among people about the effectiveness of methotrexate drug are the major factors driving the market growth.
Ans: The market size of methotrexate drug market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023 – 2035.
Ans: Side effects of methotrexate drug treatment, high cost of treatment, and less favorable medical policies and insurance are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Pfizer Inc., Silvergate Pharmaceuticals, Inc., Apotex Inc., Par Pharmaceutical, Amneal Pharmaceuticals LLC., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, LingNan Pharmaceutical, Sichuan Huiyu Pharmaceutical Co. Ltd, and Eisai Co.Ltd., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, administration, application, end user, distribution channel, and by region.
Ans: The intravenous segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
